Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10880

Shown on this page

Current sort

Institutions in Nashville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Vanderbilt University Medical Center

Live official records

Open in full search

Conditions: Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous
Interventions: Petosemtamab + Pembrolizumab; Combination Product
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: St. Petersburg, Florida • Long Island City, New York • Chattanooga, Tennessee + 3 more

Conditions: PreDiabetes, Diet, Healthy, Nutritional and Metabolic Diseases
Interventions: Whole Foods for Families; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 6 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions: Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more

Conditions: Glabellar Lines
Interventions: AGN-151586, BOTOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Glendale, Arizona • Newport Beach, California • Vista, California + 5 more

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 104
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Interventions: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 69
States / cities: Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1023
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more

Conditions: Hearing Loss, Sensorineural, Presbycusis
Interventions: Audiologist-based fitting, Over-the-counter fitting; Device
Lead sponsor: Yu-Hsiang Wu; Other
Eligibility: 18 Years to 89 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Iowa City, Iowa • Nashville, Tennessee

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 54
States / cities: Birmingham, Alabama • Anchorage, Alaska • Concord, California + 45 more

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 92
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 72 more

Conditions: NSCLC Stage IV
Interventions: N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 32
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • El Segundo, California + 26 more

Conditions: Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
Interventions: Brexucabtagene Autoleucel; Biological
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
U.S. locations: 50
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more

Clinical trials in Nashville, Tennessee

Filter and sort this location

Institutions in Nashville

Live official records

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Barriers and Facilitators to OTC Hearing Aids Success

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel